Antibody Discovery News and Research

RSS

SwiftScale Biologics: Cell-Free Synthesis of Biologics

In this interview, News-Medical talks to David Mace, CEO at SwiftScale Biologics, about the work they do in cell-free synthesis, their partnership with Sartorius and the biologics field as a whole.

From Sartorius 30 Mar 2021

Study shows substantial benefit of combination therapy for advanced Marburg infections

A new study conducted at the Galveston National Laboratory at the The University of Texas Medical Branch at Galveston has shown substantial benefit to combining monoclonal antibodies and the antiviral remdesivir against advanced Marburg virus.

25 Mar 2021

Researchers present fragment-based computational design of antibodies that target structured epitopes

A new study describes a novel fragment-based method to design antibody complementarity determining region (CDR) loops.

8 Mar 2021

Are antibody cocktails the key to COVID-19 treatment?

News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.

18 Feb 2021

Second-generation double antibody protects from SARS-CoV-2 and its tested variants

The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants. It also prevents the virus from mutating to resist the therapy.

24 Jan 2021

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

OXGENE™ announces the introduction of its self-labelling integral membrane (SLIM™) protein discovery system.

12 Jan 2021

Research at Advanced Photon Source laid the groundwork for effective COVID-19 vaccines

There is light at the end of the COVID-19 pandemic tunnel. Several vaccines against the SARS-CoV-2 virus that causes COVID-19 are now in clinical trials, with one -- developed by Pfizer/BioNTech -- already having been approved for emergency use in the United States.

18 Dec 2020

Eureka's InvisiMask human antibody nasal spray offers protection against SARS-CoV-2 in mice

Eureka Therapeutics, Inc. announced today successful preclinical results from its InvisiMask™ Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.

14 Dec 2020

£453,000 grant awarded to boost research and development for COVID-19 antibodies

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, leader in innovation and impact, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts.

14 Dec 2020

FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodies

FairJourney Biologics S.A (FJB) and IONTAS Limited, leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics.

24 Nov 2020

Monoclonal Antibodies: Discovery, Characterization and Challenges

In this interview, News-Medical talks to David Apiyo, a senior manager of applications at Sartorius AG, about monoclonal antibody development and characterization.

22 Oct 2020

Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center

Thermo Fisher Scientific, the world leader in serving science, today announced new collaborations of the Thermo Fisher Precision Medicine Science Center with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery.

From Thermo Fisher Scientific Inc. 23 Sep 2020

ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

17 Sep 2020

CARE consortium launches to accelerate drug discovery and development for COVID-19

CARE a new consortium supported by the Innovative Medicines Initiative public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.

19 Aug 2020

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Now, Regeneron Pharmaceuticals says its COVID-19 antibody-drug cocktail under development prevented and treated the disease in monkeys and hamsters, showing promise that it may work in humans.

5 Aug 2020

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.

From Fluidic Sciences and Sphere Bio 20 Jul 2020

An improved tetravalent antibody blocks SARS-CoV-2 infection

A new study published on the preprint server bioRxiv* in June 2020 shows the potential of a new fusion molecule called a biparatopic protein to inhibit viral interaction with the host cell ACE2 receptor. This could lead to therapeutic applications.

17 Jun 2020

Twist Bioscience and Serimmune collaborate to identify SARS-CoV-2 therapeutic antibody candidates

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Serimmune Inc., a leader in understanding the functional antibody repertoire’s role in human disease, today announced a collaboration to identify and evaluate SARS-CoV-2 therapeutic antibody candidates from Twist libraries.

From Twist Bioscience 10 Jun 2020

New design strategy marks a potential advance in the fight against Alzheimer's disease

Researchers have found a way to design an antibody that can identify the toxic particles that destroy healthy brain cells - a potential advance in the fight against Alzheimer's disease.

26 May 2020

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Patients infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 produce antibodies that bind to the other coronavirus, but the cross-reactive antibodies are not cross protective, at least in cell-culture experiments, researchers report May 17 in the journal Cell Reports.

18 May 2020